Arcutis Biotherapeutics ARQT
NASDAQ ARQT
$31.40 -0.81 (-2.50%)
As of: Oct 23, 2026 · 3:43 PM EDT

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022)

Updated

Analysis

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.95 Bn 1,100.53 Bn 19.71 Bn
2 Johnson & Johnson 635.80 Bn 555.66 Bn 17.30 Bn
3 AbbVie 506.62 Bn 479.73 Bn 12.70 Bn
4 Merck 358.64 Bn 313.02 Bn 12.21 Bn
5 Novartis Ag 292.18 Bn 256.17 Bn 11.24 Bn
6 Astrazeneca 265.70 Bn 239.39 Bn 12.86 Bn
7 Amgen 237.74 Bn 193.14 Bn 7.24 Bn
8 Gilead Sciences 195.25 Bn 169.45 Bn 6.22 Bn
9 Pfizer 171.25 Bn 117.90 Bn 10.94 Bn
10 Arcutis Biotherapeutics 4.09 Bn 3.37 Bn 118.92 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 802,000.00
Jun 30, 2022 396,000.00
Mar 31, 2022 392,000.00
API Access

Arcutis Biotherapeutics Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=ARQT&period=max&api_key=YOUR_API_KEY